Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-6209
- Development stage
- Phase 2
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HRS-6209 is an investigational small molecule inhibitor of cyclin-dependent kinase 4 (CDK4), developed for the treatment of advanced solid tumors, with a primary focus on breast cancer. As a CDK4 modulator, it targets cell cycle regulation to inhibit tumor cell proliferation. The drug is being evaluated in multiple phase I/II clinical trials both as monotherapy and in combination with agents such as letrozole, fulvestrant, HRS-8080, and HRS-1358 in patients with advanced unresectable or metastatic breast cancer. Early studies are assessing its safety, tolerability, pharmacokinetics, and preliminary efficacy[2][3][6][7].
- Other names
- HRS 6209HRS6209HRS-6209
02
Targets
CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on HRS-6209.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-6209.